Headlines about Zai Lab (NASDAQ:ZLAB) have been trending positive on Thursday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zai Lab earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.1933989661353 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- BidaskClub Upgrades Zai Lab (ZLAB) to “Sell” (americanbankingnews.com)
- FY2022 Earnings Estimate for Zai Lab Ltd (ZLAB) Issued By Leerink Swann (americanbankingnews.com)
- Analysts Set $38.50 Target Price for Zai Lab Ltd (ZLAB) (americanbankingnews.com)
- Zai Lab (ZLAB) Given Outperform Rating at Leerink Swann (americanbankingnews.com)
Several research firms have issued reports on ZLAB. BidaskClub upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Thursday, March 22nd. Leerink Swann restated an “outperform” rating on shares of Zai Lab in a research note on Friday, March 23rd. Finally, JPMorgan Chase & Co. upgraded Zai Lab from a “neutral” rating to an “overweight” rating and set a $32.00 price objective for the company in a research report on Wednesday, February 14th.
Zai Lab Company Profile
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.